RTOG-0522

Terminated

Return to Protocol Table

Protocol Information

Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants

A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab C225 [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas

Principal Investigator

Kian Ang

Status

Terminated

Date Opened To Accrual

November 22, 2005

Date Closed To Accrual

March 3, 2009

Date of Study Termination

May 20, 2022


Disease Site

Head and Neck [HN] Head and Neck

Phase

III

Developmental Therapeutics

No

Primary Objective

Evaluate whether the addition of cetuximab to a concurrent radiation-cisplatin regimen will improve progression-free survival in patients with locally advanced squamous cell carcinoma (SCC) of the oropharynx, hypopharynx, or larynx;

Patient Population

nSquamous cell carcinoma of the oropharynx, hypopharynx, or larynx; selected stage III-IV disease (T2N2-3M0, T3-4 any N M0)

Target Accrual

945

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.


Patient Study Webpage

There is no available patient study webpage available for this trial at this time.